[HCPLive] Sutezolid Shows Promise as Safer Oxazolidinone in Novel 4-Month TB Regimen

8 June 2026

HCPLive interview

At the 2026 American Thoracic Society International Conference, investigator Robert Wallis, MD, the chief science officer at the Aurum Institute & professor of medicine at Vanderbilt University, presented preliminary findings from the PanTB-HM phase 2c trial, which evaluated 3 novel 4-month pan-TB regimens, each containing the investigational oxazolidinone sutezolid, against standard 6-month HRZE (isoniazid, rifampicin, pyrazinamide, ethambutol) therapy in 378 adults across South Africa, Tanzania, and Mozambique.

Among participants with impaired baseline lung function (FEV1 ≤62%), recipients of the S1600BPN regimen — sutezolid 1600 mg, bedaquiline, pretomanid, and N-acetylcysteine (NAC) — demonstrated markedly superior FEV1 recovery compared with controls, a 10.6 percentage point difference at day 14 that was largely maintained through day 168. No typical oxazolidinone adverse events were observed across any experimental arm.

HCPLive spoke with Wallis during the meeting to discuss what these results may mean for clinicians managing TB-associated lung disease and the evolving role of sutezolid and NAC in next-generation TB regimens.

Read the full interview here.

Source: HCPLive